Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

The phosphoinositide 3‐kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, William J., Hentemann, Martin F., Rowley, R. Bruce, Bull, Cathy O., Jenkins, Susan, Bullion, Ann M., Johnson, Jeffrey, Redman, Anikó, Robbins, Arthur H., Esler, William, Fracasso, R. Paul, Garrison, Timothy, Hamilton, Mark, Michels, Martin, Wood, Jill E., Wilkie, Dean P., Xiao, Hong, Levy, Joan, Stasik, Enrico, Liu, Ningshu, Schaefer, Martina, Brands, Michael, Lefranc, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094563/
https://www.ncbi.nlm.nih.gov/pubmed/27310202
http://dx.doi.org/10.1002/cmdc.201600148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094563/
https://www.ncbi.nlm.nih.gov/pubmed/27310202
http://dx.doi.org/10.1002/cmdc.201600148

Ejemplares similares